Palvella Therapeutics, Inc. (PVLA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
40/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinPVLA / S&P 22.60% / 15.20% |
LosePVLA / S&P PVLA unavailable / 15.00% |
LosePVLA / S&P -10.89% / 50.40% |
| 2026-Q11/3 |
WinPVLA / S&P 19.09% / -4.33% |
LosePVLA / S&P PVLA unavailable / 11.30% |
LosePVLA / S&P -40.68% / 27.70% |
| 2025-Q41/3 |
WinPVLA / S&P 66.96% / 2.65% |
LosePVLA / S&P PVLA unavailable / 9.00% |
LosePVLA / S&P -52.62% / 13.40% |
| 2025-Q31/3 |
WinPVLA / S&P 178.13% / 8.12% |
LosePVLA / S&P PVLA unavailable / 4.61% |
LosePVLA / S&P -120.00% / 13.45% |
| 2025-Q20/3 |
LosePVLA / S&P -19.47% / 10.94% |
LosePVLA / S&P PVLA unavailable / 4.83% |
LosePVLA / S&P -169.58% / 10.63% |
| 2025-Q11/3 |
WinPVLA / S&P 133.25% / -4.27% |
LosePVLA / S&P PVLA unavailable / 4.98% |
LosePVLA / S&P -150.65% / 10.57% |
| 2024-Q40/3 |
LosePVLA / S&P -27.62% / 2.41% |
LosePVLA / S&P PVLA unavailable / 5.25% |
LosePVLA / S&P PVLA unavailable / 6.15% |
| 2024-Q31/3 |
WinPVLA / S&P 68.99% / 5.89% |
LosePVLA / S&P -97.57% / 5.89% |
LosePVLA / S&P PVLA unavailable / 6.11% |
| 2024-Q20/3 |
LosePVLA / S&P -32.98% / 4.28% |
LosePVLA / S&P -49.51% / 5.38% |
LosePVLA / S&P PVLA unavailable / 5.12% |
| 2024-Q11/3 |
LosePVLA / S&P 0.55% / 10.56% |
WinPVLA / S&P 125.21% / 5.71% |
LosePVLA / S&P PVLA unavailable / 5.59% |
| 2023-Q41/3 |
LosePVLA / S&P -38.93% / 11.69% |
WinPVLA / S&P 51.99% / 6.81% |
LosePVLA / S&P PVLA unavailable / 7.78% |
| 2023-Q32/3 |
WinPVLA / S&P 79.52% / -3.27% |
WinPVLA / S&P 57.66% / 7.52% |
LosePVLA / S&P PVLA unavailable / -5.03% |
| 2023-Q21/3 |
LosePVLA / S&P -82.99% / 8.74% |
WinPVLA / S&P 30.72% / 9.50% |
LosePVLA / S&P PVLA unavailable / -8.57% |
| 2023-Q10/3 |
LosePVLA / S&P -6.15% / 7.50% |
LosePVLA / S&P -32.80% / 10.77% |
LosePVLA / S&P PVLA unavailable / -15.69% |
| 2022-Q40/3 |
LosePVLA / S&P -9.57% / 7.56% |
LosePVLA / S&P -8.84% / 11.88% |
LosePVLA / S&P PVLA unavailable / -17.99% |
| 2022-Q31/3 |
LosePVLA / S&P -38.50% / -4.88% |
WinPVLA / S&P 26.74% / 13.47% |
LosePVLA / S&P PVLA unavailable / -1.41% |
| 2022-Q21/3 |
LosePVLA / S&P -38.28% / -16.10% |
WinPVLA / S&P 17.11% / 13.71% |
LosePVLA / S&P -30.95% / 11.04% |
| 2022-Q10/3 |
LosePVLA / S&P -19.84% / -4.60% |
LosePVLA / S&P -18.86% / 15.97% |
LosePVLA / S&P 1.47% / 42.23% |
| 2021-Q41/3 |
LosePVLA / S&P -26.89% / 11.03% |
WinPVLA / S&P 16.85% / 15.00% |
LosePVLA / S&P PVLA unavailable / 96.40% |
| 2021-Q31/3 |
WinPVLA / S&P 34.99% / 0.58% |
LosePVLA / S&P -44.45% / 10.77% |
LosePVLA / S&P PVLA unavailable / 69.42% |
| 2021-Q21/3 |
WinPVLA / S&P 49.03% / 8.55% |
LosePVLA / S&P -57.83% / 6.58% |
LosePVLA / S&P PVLA unavailable / 51.81% |
| 2021-Q10/3 |
LosePVLA / S&P 2.80% / 6.17% |
LosePVLA / S&P -33.57% / -1.06% |
LosePVLA / S&P PVLA unavailable / 7.39% |
| 2020-Q41/3 |
WinPVLA / S&P 20.77% / 12.15% |
LosePVLA / S&P -45.22% / -3.72% |
LosePVLA / S&P PVLA unavailable / -33.42% |
| 2020-Q31/3 |
LosePVLA / S&P -33.23% / 8.93% |
WinPVLA / S&P 23.36% / -2.04% |
LosePVLA / S&P PVLA unavailable / -27.10% |
| 2020-Q22/3 |
WinPVLA / S&P 35.96% / 20.54% |
WinPVLA / S&P 103.58% / -0.46% |
LosePVLA / S&P PVLA unavailable / -27.11% |
| 2020-Q11/3 |
LosePVLA / S&P -37.02% / -19.60% |
WinPVLA / S&P 43.59% / 3.47% |
LosePVLA / S&P PVLA unavailable / -14.75% |
| 2019-Q41/3 |
LosePVLA / S&P 6.16% / 9.07% |
WinPVLA / S&P 60.18% / 5.36% |
LosePVLA / S&P PVLA unavailable / 2.99% |
| 2019-Q30/3 |
LosePVLA / S&P -27.45% / 1.70% |
LosePVLA / S&P -22.17% / 5.02% |
LosePVLA / S&P PVLA unavailable / 0.21% |
| 2019-Q21/3 |
WinPVLA / S&P 40.30% / 4.30% |
LosePVLA / S&P -31.84% / 6.64% |
LosePVLA / S&P PVLA unavailable / 8.65% |
| 2019-Q12/3 |
WinPVLA / S&P 25.94% / 13.65% |
WinPVLA / S&P 14.47% / 8.12% |
LosePVLA / S&P PVLA unavailable / 14.29% |
| 2018-Q40/3 |
LosePVLA / S&P -52.50% / -13.52% |
LosePVLA / S&P 7.81% / 9.05% |
LosePVLA / S&P PVLA unavailable / 18.23% |
| 2018-Q32/3 |
WinPVLA / S&P 10.45% / 7.71% |
WinPVLA / S&P 313.15% / 10.21% |
LosePVLA / S&P PVLA unavailable / 19.06% |
| 2018-Q21/3 |
LosePVLA / S&P -25.66% / 3.43% |
WinPVLA / S&P 447.85% / 9.03% |
LosePVLA / S&P PVLA unavailable / 14.46% |
| 2018-Q11/3 |
LosePVLA / S&P -9.67% / -0.76% |
WinPVLA / S&P 361.86% / 7.68% |
LosePVLA / S&P PVLA unavailable / 12.46% |
| 2017-Q42/3 |
WinPVLA / S&P 31.08% / 6.64% |
WinPVLA / S&P 333.46% / 7.03% |
LosePVLA / S&P PVLA unavailable / 13.82% |
| 2017-Q32/3 |
WinPVLA / S&P 13.83% / 4.48% |
WinPVLA / S&P 87.83% / 5.68% |
LosePVLA / S&P PVLA unavailable / 17.57% |
| 2017-Q22/3 |
WinPVLA / S&P 94.62% / 3.09% |
WinPVLA / S&P 37.63% / 4.83% |
LosePVLA / S&P PVLA unavailable / 17.74% |
| 2017-Q12/3 |
WinPVLA / S&P 85.05% / 6.07% |
WinPVLA / S&P 49.64% / 3.67% |
LosePVLA / S&P PVLA unavailable / 13.32% |
| 2016-Q41/3 |
LosePVLA / S&P -23.14% / 3.82% |
WinPVLA / S&P 98.88% / 2.09% |
LosePVLA / S&P PVLA unavailable / 7.05% |
| 2016-Q32/3 |
WinPVLA / S&P 13.54% / 3.85% |
WinPVLA / S&P 28.92% / 0.20% |
LosePVLA / S&P PVLA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PVLA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 177.62% | 20.78% |
| Annualized return | 177.62% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PVLA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -65.27% | 83.14% |
| Annualized return | -19.06% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PVLA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 16.72% | 319.30% |
| Annualized return | 1.56% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |